Babiy V.V., Kulikov A.Y. 3644

Pharmacoeconomic analysis of combination of daclatasvir and sofosbuvir in treatment of chronic hepatitis C(genotype 3) in the Russian Federation: among treatmentexperienced patients

The objective of this study was to conduct cost-effectiveness analysis and budget impact analysis of antiviral drug treatment of chronic hepatitis C (peginterferon alfa + ribavirin 24 weeks (F0-F4), daclatasvir + sofosbuvir 12 weeks (F0-F3), daclatasvir + sofosbuvir + ribavirin 12 weeks (F4), sofosbuvir + ribavirin 24 weeks (F0-F4)) among treatment-experienced patients (HCV genotype 3). Both analyses were based on the developed pharmacoeconomic model (Markov model). Literature review showed absence of clear effectiveness data on using of peginterferon alfa + ribavirin in the targeted group therefore subsequent pharmacoeconomic analysis for this comparator was aborted. Obtained results showed that daclatasvir + sofosbuvir and daclatasvir + sofosbuvir + ribavirin was dominant in compares with sofosbuvir + ribavirin in the F0-F3 and F4 groups. In budget impact analysis total costs per one patient decreased on 283 623 rubles and 290 168 rubles in case of using daclatasvir + sofosbuvir instead of sofosbuvir + ribavirin among F0-F3 patients and daclatasvir + sofosbuvir + ribavirin instead of sofosbuvir + ribavirin among F4 patients, respectively.
Скорее всего ваш браузер не поддерживает PDF и Adobe Reader, нажмите здесь, чтобы просмотреть PDF

Comments0